Improving mRNA vaccine safety and efficiency with cationized lipid nanoparticle formula

The widespread use of Covid-19 mRNA vaccines has highlighted the need to address rare but concerning side effects. Systemic off-target gene expression has been identified as a primary cause of acute adverse reactions and side effects associated with nucleoside-modified mRNA vaccines. In this study, we incorporated the permanent cationic lipid Dotap component into the mRNA-LNP formula associated with the FDA-approved mRNA vaccine Comirnaty to create a novel positively charged LNP carrier for mRNA vaccine delivery. Using the optimized LNP formula to prepare SARS-Cov-2 Spike mRNA vaccines for immunogenicity testing, Balb/c mice exhibited improved immunogenicity kinetics with initial antibody titers being lower but showing a continuous upward trend, ultimately reaching levels comparable to those of control mRNA vaccines 8 weeks after boost immunization. The mRNA vaccines encapsulated in the modified LNPs have demonstrated a superior safety profile in respect to systemic delivery of LNP constituents, off-target gene expression, and the systemic pro-inflammatory stimulation. Consequently, it may represent a safer alternative of conventional mRNA-LNP vaccines.

[1]  D. Weissman,et al.  Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer , 2023, Science advances.

[2]  T. Nakayama,et al.  Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA‐1273 , 2022, Microbiology and immunology.

[3]  Y. Lou,et al.  Structural and biochemical characteristics of mRNA nanoparticles determine anti–SARS-CoV-2 humoral and cellular immune responses , 2022, Science advances.

[4]  K. Loré,et al.  Innate immune mechanisms of mRNA vaccines , 2022, Immunity.

[5]  Xiaohong Song,et al.  Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus , 2022, Frontiers in Immunology.

[6]  Wael Al-Jaroudi,et al.  COVID-19 vaccine-associated myocarditis , 2022, World journal of cardiology.

[7]  Xiangrong Song,et al.  mRNA Vaccines Against SARS‐CoV‐2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids , 2022, Advanced functional materials.

[8]  L. Hartling,et al.  Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review , 2022, BMJ.

[9]  T. Shimabukuro,et al.  Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe , 2022, The Lancet Infectious Diseases.

[10]  K. Whitehead,et al.  The replacement of helper lipids with charged alternatives in lipid nanoparticles facilities targeted mRNA delivery to the spleen and lungs. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Yi-Tao Yu,et al.  The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines , 2021, Frontiers in Cell and Developmental Biology.

[12]  Daniel L. Roellinger,et al.  Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Aaron M. Rosenfeld,et al.  Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2021, Immunity.

[14]  K. Khunti,et al.  Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.

[15]  C. Bogdan,et al.  Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®) , 2021, Vaccines.

[16]  D. Weissman,et al.  Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration , 2021, Communications Biology.

[17]  S. Ciesek,et al.  Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies , 2021, Journal of clinical medicine.

[18]  B. Igyártó,et al.  The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, bioRxiv.

[19]  D. Peer,et al.  Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. , 2021, ACS nano.

[20]  N. Tchitchek,et al.  Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response , 2020, Frontiers in Immunology.

[21]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[22]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[23]  Gustavo Lou,et al.  Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics , 2020, Pharmaceutics.

[24]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[25]  C. Roberts,et al.  Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[26]  A. Vojdani,et al.  Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases , 2020, Clinical Immunology.

[27]  A. Amanullah,et al.  Myocardial injury and COVID-19: Possible mechanisms , 2020, Life Sciences.

[28]  Qiang Cheng,et al.  Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing , 2020, Nature Nanotechnology.

[29]  Huijun Lu,et al.  mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice , 2020, Vaccines.

[30]  Kimberly J. Hassett,et al.  Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines , 2019, Molecular therapy. Nucleic acids.

[31]  D. Weissman,et al.  Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.

[32]  Daniel G. Anderson,et al.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination , 2016, Proceedings of the National Academy of Sciences.

[33]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[34]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.